Overview

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2004-03-24

Target enrollment:

Participant gender:

Summary

Assess the safety and efficacy of ADDERALL XR compared to placebo in the treatment of adolescents (aged 13-17) with ADHD. Subjects were assigned to one of two cohorts based on weight (<= 75 kg or > 75 kg).

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Adderall
Amphetamine